ImmuPharma股份在季度亏损和股本负回报后下跌13%,尽管开发了一种lupus药物。 ImmuPharma shares fell 13% after a quarterly loss and negative return on equity, despite developing a lupus drug.

ImmuPharma (LON:IMM) 的股份在星期一下跌了13%左右, ImmuPharma (LON:IMM) shares dropped around 13% on Monday, closing at GBX 9.05 amid heightened trading volume, following a quarterly loss of GBX 0.38 per share and a negative return on equity of 131.41%. 该公司开发了P140(LupuzorTM)治疗狼疮和自发免疫疾病,预计每年每股损失约339.00美元。 The company, developing P140 (Lupuzor™) for lupus and autoimmune diseases, faces projected annual losses of about -339.00 per share. 市场上限约为4 400万英镑,贝塔为153英镑,股票仍然波动不定,交易量超过50天和200天移动平均数。 With a market cap of roughly £44 million and a beta of 1.53, the stock remains volatile, trading above its 50-day and 200-day moving averages.